BML-190

• Description :

  BML-190 (IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively) . IC50 Value: 435 nM (Ki CB2) Target:CB2 receptor in vitro: BML-190 increases the accumulation of cAMP, via forskolin-stimulated mechanism in HEK-293 cells. Alternate studies suggest that BML-190 reduces the toxicity of culture supernatants to SH-SY5Y human neutroblastoma cells. Various research suggests that BML-190 is an essential tool in studying the proliferation of neuroblastoma. BML-190 diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. BML-190 also inhibits LPS-induced PGE2 production and COX-2 induction. in vivo:

• Product Name Alternative :

  Indomethacin morpholinylamide; IMMA

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Cannabinoid Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/BML-190.html

• Purity :

  99.53

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CC(N1C(C2=CC=C(Cl)C=C2)=O)=C(CC(N3CCOCC3)=O)C4=C1C=CC(OC)=C4

• Molecular Formula :

  C23H23ClN2O4

• Molecular Weight :

  426.89

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Zhang, Qiang; Ma, Peng; Cole, Richard B.; Wang, Guangdi In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB2) in rat liver microsomes. European Journal of Pharmaceutical Sciences (2010), 41 (1), 163-172.|[2]Klegeris, Andis; Bissonnette, Christopher J.; McGeer, Patrick L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. British Journal of Pharmacology (2003), 139 (4), 775-786.|[3]New DC, Wong YH. BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett. 2003 Feb 11;536 (1-3) :157-60.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2854-32-2]